TGF-β signalling-related markers in cancer patients with bone metastasis

Jose Baselga, Mace L. Rothenberg, Josep Tabernero, Joan Seoane, Thomas Daly, Ann Cleverly, Brandi Berry, Susanne K. Rhoades, Chad A. Ray, Jeffrey Fill, Daphne L. Farrington, Lisa Anne Wallace, Jonathan M. Yingling, Michael Lahn, Carlos Arteaga, Michael Carducci

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

We measured transforming growth factor (TGF)-β-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-β inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n = 23) and prostate cancer (n = 15). Plasma TGF-β1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml-1) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-β inhibitor.

Original languageEnglish (US)
Pages (from-to)217-236
Number of pages20
JournalBiomarkers
Volume13
Issue number2
DOIs
StatePublished - Mar 1 2008

Fingerprint

Transforming Growth Factors
Bone
Neoplasm Metastasis
Bone and Bones
Growth Inhibitors
Assays
Blood Cells
Neoplasms
Blood
Clinical Trials
Pharmacodynamics
Platelet Factor 4
Plasmas
von Willebrand Factor
Biomarkers
Interleukin-10
Prostatic Neoplasms
Breast
Proteins

Keywords

  • Cancer
  • Plasma biomarkers
  • TGF-β

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Health, Toxicology and Mutagenesis

Cite this

Baselga, J., Rothenberg, M. L., Tabernero, J., Seoane, J., Daly, T., Cleverly, A., ... Carducci, M. (2008). TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers, 13(2), 217-236. https://doi.org/10.1080/13547500701676019

TGF-β signalling-related markers in cancer patients with bone metastasis. / Baselga, Jose; Rothenberg, Mace L.; Tabernero, Josep; Seoane, Joan; Daly, Thomas; Cleverly, Ann; Berry, Brandi; Rhoades, Susanne K.; Ray, Chad A.; Fill, Jeffrey; Farrington, Daphne L.; Wallace, Lisa Anne; Yingling, Jonathan M.; Lahn, Michael; Arteaga, Carlos; Carducci, Michael.

In: Biomarkers, Vol. 13, No. 2, 01.03.2008, p. 217-236.

Research output: Contribution to journalArticle

Baselga, J, Rothenberg, ML, Tabernero, J, Seoane, J, Daly, T, Cleverly, A, Berry, B, Rhoades, SK, Ray, CA, Fill, J, Farrington, DL, Wallace, LA, Yingling, JM, Lahn, M, Arteaga, C & Carducci, M 2008, 'TGF-β signalling-related markers in cancer patients with bone metastasis', Biomarkers, vol. 13, no. 2, pp. 217-236. https://doi.org/10.1080/13547500701676019
Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A et al. TGF-β signalling-related markers in cancer patients with bone metastasis. Biomarkers. 2008 Mar 1;13(2):217-236. https://doi.org/10.1080/13547500701676019
Baselga, Jose ; Rothenberg, Mace L. ; Tabernero, Josep ; Seoane, Joan ; Daly, Thomas ; Cleverly, Ann ; Berry, Brandi ; Rhoades, Susanne K. ; Ray, Chad A. ; Fill, Jeffrey ; Farrington, Daphne L. ; Wallace, Lisa Anne ; Yingling, Jonathan M. ; Lahn, Michael ; Arteaga, Carlos ; Carducci, Michael. / TGF-β signalling-related markers in cancer patients with bone metastasis. In: Biomarkers. 2008 ; Vol. 13, No. 2. pp. 217-236.
@article{fa01b58f14a74f018296062e407fced1,
title = "TGF-β signalling-related markers in cancer patients with bone metastasis",
abstract = "We measured transforming growth factor (TGF)-β-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-β inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n = 23) and prostate cancer (n = 15). Plasma TGF-β1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml-1) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-β inhibitor.",
keywords = "Cancer, Plasma biomarkers, TGF-β",
author = "Jose Baselga and Rothenberg, {Mace L.} and Josep Tabernero and Joan Seoane and Thomas Daly and Ann Cleverly and Brandi Berry and Rhoades, {Susanne K.} and Ray, {Chad A.} and Jeffrey Fill and Farrington, {Daphne L.} and Wallace, {Lisa Anne} and Yingling, {Jonathan M.} and Michael Lahn and Carlos Arteaga and Michael Carducci",
year = "2008",
month = "3",
day = "1",
doi = "10.1080/13547500701676019",
language = "English (US)",
volume = "13",
pages = "217--236",
journal = "Biomarkers",
issn = "1354-750X",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - TGF-β signalling-related markers in cancer patients with bone metastasis

AU - Baselga, Jose

AU - Rothenberg, Mace L.

AU - Tabernero, Josep

AU - Seoane, Joan

AU - Daly, Thomas

AU - Cleverly, Ann

AU - Berry, Brandi

AU - Rhoades, Susanne K.

AU - Ray, Chad A.

AU - Fill, Jeffrey

AU - Farrington, Daphne L.

AU - Wallace, Lisa Anne

AU - Yingling, Jonathan M.

AU - Lahn, Michael

AU - Arteaga, Carlos

AU - Carducci, Michael

PY - 2008/3/1

Y1 - 2008/3/1

N2 - We measured transforming growth factor (TGF)-β-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-β inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n = 23) and prostate cancer (n = 15). Plasma TGF-β1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml-1) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-β inhibitor.

AB - We measured transforming growth factor (TGF)-β-dependent biomarkers in plasma and in peripheral blood mononuclear cells (PBMCs) to identify suitable pharmacodynamic markers for future clinical trials with TGF-β inhibitors. Forty-nine patients with bone metastasis were enrolled in the study, including patients with breast (n = 23) and prostate cancer (n = 15). Plasma TGF-β1 levels were elevated in more than half of the cancer patients (geometric mean 2.63 ng ml-1) and positively correlated with increased platelet factor 4 (PF4) levels, parathyroid-related protein (PTHrP), von Willebrand Factor (vWF) and interleukin (IL)-10. PBMC were stimulated ex vivo to determine the individual biological variability of an ex vivo assay measuring pSMAD expression. This assay performed sufficiently well to allow its future use in a clinical trial of a TGF-β inhibitor.

KW - Cancer

KW - Plasma biomarkers

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=39149139338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39149139338&partnerID=8YFLogxK

U2 - 10.1080/13547500701676019

DO - 10.1080/13547500701676019

M3 - Article

C2 - 18270872

AN - SCOPUS:39149139338

VL - 13

SP - 217

EP - 236

JO - Biomarkers

JF - Biomarkers

SN - 1354-750X

IS - 2

ER -